Purpose: To determine whether testosterone supplementation is associated with retinal artery occlusion (RAO) or retinal vein occlusion (RVO).
R
etinal vascular occlusions, which include retinal artery occlusion (RAO) and retinal vein occlusion (RVO), are the second most common causes of blindness from retinal vascular disease. [1] [2] [3] Retinal artery occlusion and RVO can occur secondary to endogenous and exogenous thrombosis, embolization, vasculitis, or vasospasm and can result in significant permanent vision loss. [4] [5] [6] [7] [8] [9] Both common systemic cardiovascular risk factors (i.e., hypertension (HTN), hyperlipidemia, diabetes mellitus, etc.), as well as less common hypercoaguable states (i.e., protein C or protein S deficiency, hyperhomocysteinemia, etc.) can predispose patients to develop RAO. 4, 5 Many of these same patients are also at risk of developing RVO because of the calcification of arterial walls impinging retinal veins, which can lead to narrowing and stasis and ultimately resulting in venous thrombosis. 10, 11 Another, more recently recognized cause of vascular thrombosis is the use of hormone replacement therapy. The use of oral estrogen-progestin contraceptives, 8, 12 clomiphene citrate, 13 and estrogen replacement therapies 7, 14 has been associated with both RAOs [15] [16] [17] and RVOs. 13, [18] [19] [20] [21] [22] Multiple reports have also implicated exogenous androgenic hormone regimens in the development of thrombotic and cardiovascular events in patients with and without a previously undiagnosed thrombophilia-hypofibrinolysis. 23, 24 Indications for supplemental testosterone use include low libido, infertility, hair loss, prostate cancer, and sarcopenia, [25] [26] [27] and its use has increased dramatically worldwide in men since 2000. 25, 28 With this increase, a greater focus has been placed on identifying the potential risks of exogenous testosterone. To date, direct clinical evidence for a possible link to vascular disease has primarily been derived from case reports. 23, 24, 29, 30 Recently, however, a large metaanalysis found compelling evidence that 1 year of supplemental testosterone therapy significantly increased coronary artery noncalcified and total plaque volumes compared with a placebo group. 31 Specific to testosterone's potential role in retinal disease, basic science studies have found androgen receptors and enzymes in endothelial cells 32, 33 and in retinal tissue, [34] [35] [36] [37] as well as a proinflammatory effect of testosterone in vascular endothelial cells. 38 To date, no studies have evaluated the risk of retinal occlusive disease with exogenous testosterone. The aim of this study was to determine whether supplemental testosterone use is associated with RAO or RVO.
Methods

Data Source
The Clinformatics Data Mart Database (OptumInsight, Eden Prairie, MN) is a deidentified administrative medical claims database containing the records of all enrollees in a large insurance network from across the United States. The data set includes demographic (age, sex, and race) data, all outpatient medical claims (office visits and associated diagnoses for ocular and nonocular medical conditions), and all outpatient pharmaceutical prescriptions filled for each participant enrolled in the insurance plan from January 1, 2000, to December 31, 2013. All individuals in the medical plan had full pharmacy coverage during their time enrolled. The University of Pennsylvania's Institutional Review Board deemed this study exempt from review because of the deidentified nature of the data.
Cohorts
We identified a cohort of exposed individuals based on filling a prescription for testosterone in any of the following forms: oral, topical gel, patch, or intramuscular. Other inclusion criteria required patients to be male, to have at least 2 years of continuous data in the data set and one or more visits to an eye care provider before their first testosterone prescription (the index date). Individuals were also excluded for specific systemic diseases associated with increased risk of thrombosis, disorders associated with increased testosterone, or with any medication use known to have androgen or antiandrogen effects, including patients with recorded ICD-9 codes for collagen vascular disease, coagulopathy, sickle cell disease, homocystinuria, platelet abnormalities, hyperviscosity, or testicular cancer, or one or more prescriptions for antiandrogen medications, including aromatase inhibitors: anastrozole, exemestane, toremifene citrate, fulvestrant, letrozole, and testolactone. Finally, to decrease the likelihood of misdiagnosis, all patients with an ocular history of intraocular surgery (within 90 days before the index date), diabetic retinopathy, glaucoma, optic disk drusen, Susac syndrome, RAO, RVO, giant-cell arteritis, or nonarteritic anterior ischemic optic neuropathy were also excluded (see Table, Supplemental Digital Content 1, for all ICD-9 codes used in this study; http://links.lww.com/IAE/A718).
An unexposed cohort was also created consisting of five matched controls for every eligible case. The controls were matched on age (±3 years), race, sex, and starting and ending eligibility time within the insurance plan (±3 months). The same index date as the matched case was assigned to the controls. Matched cases were also required to meet all the same inclusion and exclusion criteria as the exposed cohort.
Outcome and Covariates of Interest
The primary outcome of interest was an incident diagnosis of RAO and RVO or a combined outcome of either RAO or RVO. Additional covariates of interest were history of diabetes mellitus (without a previous diagnosis of retinopathy) and HTN.
Statistical Analysis
Baseline demographic data were evaluated at the time of the index date. Characteristics for the exposed and unexposed cohorts were summarized using mean values and SDs for continuous variables, and frequencies and percentages for categorical variables. The hazard of RAO, RVO, and the combined outcome were determined using Cox proportional hazard regression model with censoring for end of eligibility or incidence of any of the above exclusion criteria after the index date. SAS version 9.4 (SAS Institute Inc, Cary, NC) software was used for all statistical analyses. 
Results
The exposed cohort consisted of 35,784 users of testosterone and 178,860 unexposed matched controls (Figure 1 ). Within the testosterone cohort, 93 (0.3%) RAOs, 50 (0.1%) RVOs, and 126 (0.4%) combined outcomes were found. This was compared with 316 (0.2%) RAOs, 232 (0.1%) RVOs, and 532 (0.3%) combined outcomes in the unexposed cohort. The mean age of patients in the testosterone cohort was 54.9 ± 12.0 (years ± SD) and in the controls was 54.7 ± 12.1 (P = 0.01) ( Table 1 ). The racial distribution was similar for both cohorts with 34.2% white, 2.9% black, 3.5% Hispanic, 0.70% Asian, and 58.7% unknown (P = 1.00). The testosterone cohort had significantly more patients with diabetes mellitus (26.1% vs. 13.9%, P = 0.005) and HTN (63.8% vs. 45.8%, P = 0.006).
Univariate analysis (Table 2 ) revealed that increasing age, diabetes mellitus, and HTN were each associated with an increasing hazard of each of the outcomes (P , 0.01 for all comparisons). Race was not significantly associated with the development of any of the outcomes (P . 0.12 for all comparisons). Testosterone supplementation was associated with a significantly increased hazard ratio (HR) for RAO (HR: 1.52, 95% confidence interval [CI]: 1.21-1.93, P , 0.001) and the combined outcome (HR: 1.23, 95% CI: 1.01-1.48, P = 0.04) but was not associated with RVOs (HR: 1.11, 95% CI: 0.81-1.53, P = 0.51).
After controlling for all covariates of interest, multivariate analysis (Table 3) showed that testosterone supplementation was associated with an increased hazard of RAO (HR: 1.43, 95% CI: 1.12-1.81, P = 0.004), but not of RVO (HR: 1.03, 95% CI: 0.74-1.42, P = 0.86), or the combined RAO/RVO outcome (HR: 1.14, 95% CI: 0.94-1.38, P = 0.18). Increasing age and HTN also continued to be associated with an increased hazard of each of the three outcomes (P , 0.007 for all comparisons).
Discussion
Although the overall incidence of RAO in patients using supplemental testosterone in this study was low (0.3%), this use demonstrated a 43% increased hazard of developing an RAO. We did not find an association with RVOs. Despite this low incidence, the increasing use of testosterone may still lead to significant ramifications for the health of its users, given the impact thrombotic events can have on a patient's wellbeing. The exact mechanisms underlying increased risk of vascular occlusion with testosterone use are unknown but likely involve multiple factors. Many arterial thrombotic diseases are believed to occur secondary to platelet activation. 39 Rupture of an atherosclerotic plaque results in recruitment of platelets. This propagates a cyclical process of thrombus formation by platelet binding and release of platelet factors, resulting in further platelet recruitment, adhesion, and activation. 24, 39 In a recent study in men given supplemental testosterone therapy for 1 year, a significantly greater increase in both coronary artery noncalcified and total plaque volume was seen compared with the placebo group as measured by coronary computed tomographic angiography. 31 This effect on arterial plaque volume in coronary arteries may also occur elsewhere in the body, increasing the risk of plaque rupture and distal arterial occlusion, including RAO.
In addition to thrombus formation, testosterone may also directly affect platelets. Androgen receptors have been found on mammalian platelets 40 and may regulate the expression of thromboxane A2 in platelets. 41 It is through this mechanism that testosterone may cause a similar effect to that described in patients receiving supplemental estrogen and progesterone. One study in women receiving hormone-replacement therapy for 12 weeks reported a significant increase in the amount of circulating activated platelets. 30 Furthermore, dihydrotestosterone in endothelial cells has been found to induce vascular cell adhesion molecule-1 expression, which increased monocyte binding to the endothelium and acute coronary events. 32 Despite this circumstantial evidence, the exact role of how hormonereplacement therapy is related to venous thrombosis is still unclear, as platelets play a significant role in thrombosis and hemostasis in conditions of high shear stress, which generally does not occur in the venous circulation. 42 We did not find an association between supplemental testosterone use in men and RVOs. In one case series of women who developed vascular thrombosis, including RVO, while on testosterone therapy, all three women were found to have gene mutations predisposing them to thrombophilia and/or hypofibrinolysis. 23 It is possible that there is a differential effect of testosterone between the sexes, which was not evaluated in our study. In addition, we excluded patients with known predisposing conditions to thrombophilia. It is possible that testosterone may still pose additional risks in these patients. Further studies are needed to better understand testosterone use in patients with thrombophilia or hypofibrinolysis to better counsel them when considering supplemental testosterone use. This study had several strengths. First, the matched cohort study design allows for both a reduction in selection bias, as well as for studying the temporal sequence of exposure and outcome. Next, we were able to access data on a large sample of insured individuals throughout the United States, which allowed for a better powered study. Finally, because we obtained the medication usage from the pharmacy records, instead of patient self-reports, recall bias was eliminated.
Our study also has several limitations that need to be considered. First, because of the nature of the claims data, we could not access chart level data to verify diagnoses. Lacking this access may have led to some patients being erroneously included or excluded as RAO or RVO. However, this would only be problematic if there was a difference in the misclassification between the exposed and unexposed cohorts, and it is unlikely that physicians would be influenced for or against diagnosing RAO or RVO because of a testosterone prescription. Next, given the study design, we were not able to control for nonprescription or overthe-counter testosterone supplements that may have been used by other patients in either cohort. Because unexposed patients would in actuality be exposed, this would bias toward the null, suggesting that our estimate of the true association is low. Finally, because all patients included in the study had health insurance, the results may not be generalizable to the greater population, especially to the patients who do not have insurance or are enrolled in other insurance systems.
Last, it should be noted that as with any observational study, confounding is of the utmost concern. We attempted to reduce this by excluding all patients with any history of diseases that would predispose someone to forming retinal emboli or vein occlusion, as well as all patients who had a prescription for a medication that may impact systemic androgen levels. Despite these efforts, residual confounding or unmeasured confounding may exist within our results. For example, we were unable to control for plasma fibrinogen or lipoprotein levels which may influence any specific person's likelihood for an emboli or clot. Similarly, although we were able to control for HTN as a diagnosis, we were unable to control for specific systolic blood pressure levels, limiting our ability to discern between HTN that is well or poorly controlled.
In this study, we evaluated the occurrence of RAO and RVO in men using supplemental testosterone therapy and found a significantly increased risk of developing RAO in those patients. As patients using testosterone supplements are at greater risk of retinal vascular occlusions, this diagnosis should encourage prompt referral for evaluation of other cardiovascular risk factors. Furthermore, education of patients of risk associated with supplemental testosterone therapy before initiation can promote early intervention and guide management if an adverse event occurs.
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